Dose escalation trial of BNT152+153 in patients with cancer

2023-509508-13-00 Protocol BNT152-01C Human pharmacology (Phase I) - First administration to humans Ended

Start 4 Oct 2022 · End 11 Sep 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol BNT152-01C

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 4
Countries 1
Sites 1

Various solid tumors that are metastatic or unresectable

Key facts

Sponsor
BioNTech SE
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
4 Oct 2022 → 11 Sep 2025
Decision date (initial)
2024-02-08
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-509508-13-00
EudraCT number
2021-005599-20
ClinicalTrials.gov
NCT04710043

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Various solid tumors that are metastatic or unresectable

VersionLevelCodeTermSystem organ class
20.0 LLT 10025648 Malignant mast cell tumors unspecified site extranodal and solid organ sites 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

BioNTech SE

Sponsor organisation
BioNTech SE
Address
An Der Goldgrube 12, Oberstadt Oberstadt
City
Mainz
Postcode
55131
Country
Germany

Scientific contact point

Organisation
BioNTech SE
Contact name
Clinical Trial Information Desk

Public contact point

Organisation
BioNTech SE
Contact name
Clinical Trial Information Desk

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 2 1
Rest of world
United States
2

Investigational sites

Czechia

1 site · Ended
Masarykuv Onkologicky Ustav
Klinika komplexní onkologické péče, Zluty Kopec 543/7, Stare Brno, Brno-Stred

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2022-10-04 2025-09-10 2022-10-18 2025-03-05

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-12-14 Czechia Acceptable
2024-02-07
2024-02-08
2 SUBSTANTIAL MODIFICATION SM-1 2024-03-15 Czechia Acceptable
2024-06-19
2024-06-20
3 SUBSTANTIAL MODIFICATION SM-2 2024-07-15 Czechia Acceptable
2024-09-13
2024-09-16
4 SUBSTANTIAL MODIFICATION SM-3 2025-05-08 Czechia Acceptable
2025-08-18
2025-08-19